Výsledky vyhledávání - Deborah Keefe

  • Zobrazuji výsledky 1 - 13 z 13
Upřesnit hledání
  1. 1
    Trastuzumab‐associated cardiotoxicity

    Trastuzumab‐associated cardiotoxicity Autor Deborah Keefe

    Vydáno 2002
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial

    Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial Autor Daniel Duprez, Mark Munger, Jaco Botha, Deborah Keefe, Alan N. Charney

    Vydáno 2009
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension

    Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension Autor Toshio Kushiro, Hiroshige Itakura, Yoshihisa Abo, Hiromi Gotou, Shinji Terao, Deborah Keefe

    Vydáno 2006
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension

    Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension Autor Jens Jordan, Stefan Engeli, Sam W. Boye, Stéphanie Le Breton, Deborah Keefe

    Vydáno 2007
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation.

    Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation. Autor Janice B. Schwartz, Deborah Keefe, Robert E. Kates, E Kirsten, D C Harrison

    Vydáno 1982
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Antihypertensive Efficacy of the Oral Direct Renin Inhibitor Aliskiren as Add‐On Therapy in Patients Not Responding to Amlodipine Monotherapy

    Antihypertensive Efficacy of the Oral Direct Renin Inhibitor Aliskiren as Add‐On Therapy in Patients Not Responding to Amlodipine Monotherapy Autor Waymon Drummond, Mark Munger, Mohammed Rafique, Mojdeh Maboudian, Md Mahmudul Hasan Khan, Deborah Keefe

    Vydáno 2007
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin <i>vs</i> placebo or empagliflozin in patients with type 2 diabetes and heart failure

    Effects of the dual sodium–glucose linked transporter inhibitor, licogliflozin <i>vs</i> placebo or empagliflozin in patients with type 2 diabetes and heart failure Autor Rudolf A. de Boer, Julio Núñez, Plamen Kozlovski, Yi Wang, Pieter Proot, Deborah Keefe

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension

    Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension Autor William B. White, Robert S. Bresalier, Allen P. Kaplan, Biff F. Palmer, Robert H. Riddell, Anastasia Lesogor, William Chang, Deborah Keefe

    Vydáno 2010
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Efficacy and Safety of Fasudil in Patients With Stable Angina

    Efficacy and Safety of Fasudil in Patients With Stable Angina Autor Ralph Vicari, Bernard Chaitman, Deborah Keefe, William Smith, Steven G. Chrysant, Melvin J. Tonkon, Neville Bittar, Robert Weiss, Hugo Morales-Ballejo, Udho Thadani

    Vydáno 2005
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

    Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind rand... Autor Christine Bodemer, Andrzej Kaszuba, Külli Kingo, Athanasios Tsianakas, Akimichi Morita, Enrique Rivas, P. Papanastasiou, Deborah Keefe, Manmath Patekar, Pascal Charef, L. Zhang, Susan Cafoncelli, C. Papavassilis

    Vydáno 2020
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*

    Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized contro... Autor Matthias Augustin, Kristian Reich, Paul S. Yamauchi, Andreas Pinter, Jerry Bagel, Swapnil Dahale, R. You, Gerard Bruin, Jimena Djimopoulos, Bertrand Paguet, Pascal Charef, Manmath Patekar, Deborah Keefe

    Vydáno 2022
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

    Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study Autor Miguel R. Abboud, Rodolfo Delfini Cançado, Mariane de Montalembert, Wally R. Smith, Hala Rimawi, Ersi Voskaridou, Birol Güvenç, Deborah Keefe, Kai Grosch, Michele L. Nassin, Jimmy Watson, Justin Yssel, Evgeniya Reshetnyak, Yvonne Adomakoh

    Vydáno 2023
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

    Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Cl... Autor Alice B. Gottlieb, Atul Deodhar, Iain B. McInnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B. Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, C. Papavassilis, Piotr Jagiello, P. Papanastasiou, Philip J. Mease, Mark Lebwohl

    Vydáno 2022
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: